The poster of the study conducted by Genekor’s Scientific Team "Different Copy Number Variations (CNVs) account for 10.4% of pathogenic variants in 1418 patients referred for hereditary breast cancer testing" was presented at the San Antonio Breast Cancer Symposium 2021.
read moreDaphne Karavokyri shares her new documentary on Hereditary Cancer and the HerediGene genetic test she undertook at Genekor.
read moreArticle in "The Doctor" magazine by members of the scientific research team of hereditary cancer of Genekor Medical.They write: Konstantinos Agiannitopoulos Molecular Biologist, MSc, PhD & Despina Apostolopoulou Molecular Biologist, MSc, PhD
read moreToday Genekor is at the front line of modern medicine.
read moreRxPONDER Study Results Demonstrate that the Oncotype DX®
Test Can Now Spare Chemotherapy Use in the Majority of Women
with Node-positive Early-stage Breast Cancer.
Elena is sharing with us her story.
read moreThe story of surviving cancer through the eyes of a young woman named Elsa.
read morePrIMe assay is a 500+ Gene panel- test that also analyses immunotherapy biomarkers MSI, TMB and PD-L1. It is one of the most detailed, sensitive and specific tests for the tumor biology configuration, enabling physicians to plan an efficient targeted treatment plan for the patient, including immuotherapies.
read moreThe FDA has approved the use of TMB (Tumor Mutation Burden) detection as a biomarker for the selection of pembrolizumab (Keytruda™) as a treatment for adults and pediatric patients with incurable or metastatic solid tumors.
read more
